Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patients
Despite the extraordinary advances achieved to beat COVID-19 disease, many questions remain unsolved, including the mechanisms of action of SARS-CoV-2 and which factors determine why individuals respond so differently to the viral infection. Herein, we performed an in silico analysis to identify hos...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-09-01
|
| Series: | Molecular Therapy: Nucleic Acids |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253122001585 |
| _version_ | 1818244667177697280 |
|---|---|
| author | Maria Calderon-Dominguez Eva Trejo-Gutierrez Almudena González-Rovira Lucía Beltrán-Camacho Marta Rojas-Torres Sara Eslava-Alcón Daniel Sanchez-Morillo Juan Calderon-Dominguez Mª Pilar Martinez-Nicolás Estibaliz Gonzalez-Beitia Mª Dolores Nieto-Martín Teresa Trujillo-Soto Manuel A. Rodríguez-Iglesias Juan A. Moreno Rafael Moreno-Luna Mª Carmen Durán-Ruiz |
| author_facet | Maria Calderon-Dominguez Eva Trejo-Gutierrez Almudena González-Rovira Lucía Beltrán-Camacho Marta Rojas-Torres Sara Eslava-Alcón Daniel Sanchez-Morillo Juan Calderon-Dominguez Mª Pilar Martinez-Nicolás Estibaliz Gonzalez-Beitia Mª Dolores Nieto-Martín Teresa Trujillo-Soto Manuel A. Rodríguez-Iglesias Juan A. Moreno Rafael Moreno-Luna Mª Carmen Durán-Ruiz |
| author_sort | Maria Calderon-Dominguez |
| collection | DOAJ |
| description | Despite the extraordinary advances achieved to beat COVID-19 disease, many questions remain unsolved, including the mechanisms of action of SARS-CoV-2 and which factors determine why individuals respond so differently to the viral infection. Herein, we performed an in silico analysis to identify host microRNA targeting ACE2, TMPRSS2, and/or RAB14, all genes known to participate in viral entry and replication. Next, the levels of six microRNA candidates previously linked to viral and respiratory-related pathologies were measured in the serum of COVID-19-negative controls (n = 16), IgG-positive COVID-19 asymptomatic individuals (n = 16), and critical COVID-19 patients (n = 17). Four of the peripheral microRNAs analyzed (hsa-miR-32-5p, hsa-miR-98-3p, hsa-miR-423-3p, and hsa-miR-1246) were upregulated in COVID-19 critical patients compared with COVID-19-negative controls. Moreover, hsa-miR-32-5p and hsa-miR-1246 levels were also altered in critical versus asymptomatic individuals. Furthermore, these microRNA target genes were related to viral infection, inflammatory response, and coagulation-related processes. In conclusion, SARS-CoV-2 promotes the alteration of microRNAs targeting the expression of key proteins for viral entry and replication, and these changes are associated with disease severity. The microRNAs identified could be taken as potential biomarkers of COVID-19 progression as well as candidates for future therapeutic approaches against this disease. |
| first_indexed | 2024-12-12T14:20:40Z |
| format | Article |
| id | doaj.art-5aac4e0625ca49348da637a0be156193 |
| institution | Directory Open Access Journal |
| issn | 2162-2531 |
| language | English |
| last_indexed | 2024-12-12T14:20:40Z |
| publishDate | 2022-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Nucleic Acids |
| spelling | doaj.art-5aac4e0625ca49348da637a0be1561932022-12-22T00:21:47ZengElsevierMolecular Therapy: Nucleic Acids2162-25312022-09-01297687Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patientsMaria Calderon-Dominguez0Eva Trejo-Gutierrez1Almudena González-Rovira2Lucía Beltrán-Camacho3Marta Rojas-Torres4Sara Eslava-Alcón5Daniel Sanchez-Morillo6Juan Calderon-Dominguez7Mª Pilar Martinez-Nicolás8Estibaliz Gonzalez-Beitia9Mª Dolores Nieto-Martín10Teresa Trujillo-Soto11Manuel A. Rodríguez-Iglesias12Juan A. Moreno13Rafael Moreno-Luna14Mª Carmen Durán-Ruiz15Biomedicine, Biotechnology and Public Health Department, Cádiz University, 11002 Cádiz, Spain; Biomedical Research and Innovation Institute of Cadiz (INiBICA), 11009 Cádiz, SpainBiomedicine, Biotechnology and Public Health Department, Cádiz University, 11002 Cádiz, SpainBiomedicine, Biotechnology and Public Health Department, Cádiz University, 11002 Cádiz, Spain; Biomedical Research and Innovation Institute of Cadiz (INiBICA), 11009 Cádiz, SpainBiomedicine, Biotechnology and Public Health Department, Cádiz University, 11002 Cádiz, Spain; Biomedical Research and Innovation Institute of Cadiz (INiBICA), 11009 Cádiz, SpainBiomedicine, Biotechnology and Public Health Department, Cádiz University, 11002 Cádiz, Spain; Biomedical Research and Innovation Institute of Cadiz (INiBICA), 11009 Cádiz, SpainBiomedicine, Biotechnology and Public Health Department, Cádiz University, 11002 Cádiz, Spain; Biomedical Research and Innovation Institute of Cadiz (INiBICA), 11009 Cádiz, SpainBiomedical Research and Innovation Institute of Cadiz (INiBICA), 11009 Cádiz, Spain; Biomedical Engineering and Telemedicine Research Group, Department of Automation Engineering, Electronics and Computer Architecture and Networks, Universidad de Cádiz, 11009 Cádiz, SpainBiomedical Research and Innovation Institute of Cadiz (INiBICA), 11009 Cádiz, SpainOccupational Health Service, National Paraplegic Hospital, SESCAM, 45071 Toledo, SpainOccupational Health Service, National Paraplegic Hospital, SESCAM, 45071 Toledo, SpainInternal Medicine Department, University Hospital Virgen del Rocío, Seville, SpainBiomedical Research and Innovation Institute of Cadiz (INiBICA), 11009 Cádiz, Spain; UGC Microbiología, University Hospital Puerta del Mar, Avda. Ana de Viya 21, 11009 Cádiz, SpainBiomedicine, Biotechnology and Public Health Department, Cádiz University, 11002 Cádiz, Spain; Biomedical Research and Innovation Institute of Cadiz (INiBICA), 11009 Cádiz, Spain; UGC Microbiología, University Hospital Puerta del Mar, Avda. Ana de Viya 21, 11009 Cádiz, SpainCell Biology, Physiology and Immunology Department, Agrifood Campus of International Excellence (ceiA3), University of Cordoba, 14014 Córdoba, Spain; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), UGC Nephrology, Hospital Universitario Reina Sofia, 14004 Cordoba, SpainLaboratory of Neuroinflammation, National Paraplegic Hospital, SESCAM, 45071 Toledo, SpainBiomedicine, Biotechnology and Public Health Department, Cádiz University, 11002 Cádiz, Spain; Biomedical Research and Innovation Institute of Cadiz (INiBICA), 11009 Cádiz, Spain; Corresponding author Mª Carmen Duran-Ruiz, PhD, Biomedicine, Biotechnology and Public Health Department, Science Faculty, Institute of Biomedical Research of Cádiz (INiBICA), Cádiz University, Torre Sur. Avda. República Saharaui S/N, Polígono Río San Pedro, C.P. 11519 Puerto Real, Spain.Despite the extraordinary advances achieved to beat COVID-19 disease, many questions remain unsolved, including the mechanisms of action of SARS-CoV-2 and which factors determine why individuals respond so differently to the viral infection. Herein, we performed an in silico analysis to identify host microRNA targeting ACE2, TMPRSS2, and/or RAB14, all genes known to participate in viral entry and replication. Next, the levels of six microRNA candidates previously linked to viral and respiratory-related pathologies were measured in the serum of COVID-19-negative controls (n = 16), IgG-positive COVID-19 asymptomatic individuals (n = 16), and critical COVID-19 patients (n = 17). Four of the peripheral microRNAs analyzed (hsa-miR-32-5p, hsa-miR-98-3p, hsa-miR-423-3p, and hsa-miR-1246) were upregulated in COVID-19 critical patients compared with COVID-19-negative controls. Moreover, hsa-miR-32-5p and hsa-miR-1246 levels were also altered in critical versus asymptomatic individuals. Furthermore, these microRNA target genes were related to viral infection, inflammatory response, and coagulation-related processes. In conclusion, SARS-CoV-2 promotes the alteration of microRNAs targeting the expression of key proteins for viral entry and replication, and these changes are associated with disease severity. The microRNAs identified could be taken as potential biomarkers of COVID-19 progression as well as candidates for future therapeutic approaches against this disease.http://www.sciencedirect.com/science/article/pii/S2162253122001585MT: Non-coding RNAsCOVID-19miRNAbiomarkersin silico analysisACE2 |
| spellingShingle | Maria Calderon-Dominguez Eva Trejo-Gutierrez Almudena González-Rovira Lucía Beltrán-Camacho Marta Rojas-Torres Sara Eslava-Alcón Daniel Sanchez-Morillo Juan Calderon-Dominguez Mª Pilar Martinez-Nicolás Estibaliz Gonzalez-Beitia Mª Dolores Nieto-Martín Teresa Trujillo-Soto Manuel A. Rodríguez-Iglesias Juan A. Moreno Rafael Moreno-Luna Mª Carmen Durán-Ruiz Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patients Molecular Therapy: Nucleic Acids MT: Non-coding RNAs COVID-19 miRNA biomarkers in silico analysis ACE2 |
| title | Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patients |
| title_full | Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patients |
| title_fullStr | Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patients |
| title_full_unstemmed | Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patients |
| title_short | Serum microRNAs targeting ACE2 and RAB14 genes distinguish asymptomatic from critical COVID-19 patients |
| title_sort | serum micrornas targeting ace2 and rab14 genes distinguish asymptomatic from critical covid 19 patients |
| topic | MT: Non-coding RNAs COVID-19 miRNA biomarkers in silico analysis ACE2 |
| url | http://www.sciencedirect.com/science/article/pii/S2162253122001585 |
| work_keys_str_mv | AT mariacalderondominguez serummicrornastargetingace2andrab14genesdistinguishasymptomaticfromcriticalcovid19patients AT evatrejogutierrez serummicrornastargetingace2andrab14genesdistinguishasymptomaticfromcriticalcovid19patients AT almudenagonzalezrovira serummicrornastargetingace2andrab14genesdistinguishasymptomaticfromcriticalcovid19patients AT luciabeltrancamacho serummicrornastargetingace2andrab14genesdistinguishasymptomaticfromcriticalcovid19patients AT martarojastorres serummicrornastargetingace2andrab14genesdistinguishasymptomaticfromcriticalcovid19patients AT saraeslavaalcon serummicrornastargetingace2andrab14genesdistinguishasymptomaticfromcriticalcovid19patients AT danielsanchezmorillo serummicrornastargetingace2andrab14genesdistinguishasymptomaticfromcriticalcovid19patients AT juancalderondominguez serummicrornastargetingace2andrab14genesdistinguishasymptomaticfromcriticalcovid19patients AT mapilarmartineznicolas serummicrornastargetingace2andrab14genesdistinguishasymptomaticfromcriticalcovid19patients AT estibalizgonzalezbeitia serummicrornastargetingace2andrab14genesdistinguishasymptomaticfromcriticalcovid19patients AT madoloresnietomartin serummicrornastargetingace2andrab14genesdistinguishasymptomaticfromcriticalcovid19patients AT teresatrujillosoto serummicrornastargetingace2andrab14genesdistinguishasymptomaticfromcriticalcovid19patients AT manuelarodrigueziglesias serummicrornastargetingace2andrab14genesdistinguishasymptomaticfromcriticalcovid19patients AT juanamoreno serummicrornastargetingace2andrab14genesdistinguishasymptomaticfromcriticalcovid19patients AT rafaelmorenoluna serummicrornastargetingace2andrab14genesdistinguishasymptomaticfromcriticalcovid19patients AT macarmenduranruiz serummicrornastargetingace2andrab14genesdistinguishasymptomaticfromcriticalcovid19patients |